RR4 Antibody

What are R4 antibodies and what do they target in biological systems?

R4 antibodies target different antigens depending on the research context. In immunological research, anti-R4 antibodies enable detection and measurement of the R4 antigen in biological samples. This target is reported as a synonym of the CD1A gene, which encodes the CD1a molecule known to function in adaptive immune responses. The human version of R4 has a canonical amino acid length of 327 residues and a protein mass of 37.1 kilodaltons, primarily localized in the cell membrane and expressed in the tonsil, thymus, and skin . In bacterial studies, R4 refers to a specific protein found in Streptococcus agalactiae (Group B Streptococcus), which possesses distinctive antigenic determinants important for serotyping and immunological characterization .

How do R4 antibodies differ from other antibody types in immunological research?

R4 antibodies possess unique epitope recognition properties that distinguish them from other antibodies. For instance, in Streptococcus agalactiae research, R4 antibodies display two distinct antigenic determinants: one shared with Alp3 (termed "R4/Alp3 common") and another unique to R4 (termed "R4 specific"). This dual recognition property makes R4 antibodies particularly valuable for distinguishing between bacterial strains that may express similar but not identical surface proteins. Unlike antibodies targeting the C-terminus or N-terminus of proteins like tau, which have shown limited efficacy in clinical trials, antibodies targeting mid-domain regions like R4 have demonstrated better potential for preventing protein aggregate spreading in neurodegenerative disease research .

What are the primary applications of R4 antibodies in different research fields?

R4 antibodies serve diverse research applications across multiple fields:

• Immunology: Used to detect and measure R4 antigen in adaptive immune response studies

• Microbiology: Employed for serotyping and characterization of Streptococcus agalactiae strains

• Cancer research: Anti-Robo4 (R4) antibodies are used for tumor vascular targeting in antibody-drug conjugate (ADC) development

• Neurodegenerative disease research: Used to target specific domains of tau protein to prevent pathological spread

• Molecular biology: Common applications include Western Blot, ELISA, Flow Cytometry, and Immunohistochemistry

What are the optimal methods for producing functional R4 antibodies for research?

The production of high-quality R4 antibodies requires careful consideration of several key factors. For Streptococcus agalactiae R4 protein antibodies, extraction by trypsin digestion followed by sequential precipitation with trichloroacetic acid and ammonium sulfate has proven effective . For cell-internalizing anti-Robo4 antibodies, phage display-based high-throughput screening systems have successfully isolated antibodies with desired properties. This approach involves simultaneous examination of cell-internalizing activities of several hundred independent mAbs, allowing researchers to select those with optimal internalization characteristics .

When developing cell-internalizing antibodies against targets like Robo4, it's crucial to assess binding kinetics. High-quality antibodies typically demonstrate association rates (ka) of approximately 1.14 × 10^6 M^-1s^-1 and dissociation rates (kd) of around 4.19 × 10^-4 s^-1, resulting in dissociation constants (KD) in the range of 2.22 × 10^-10 M, as observed with effective R4-13i antibodies .

How can researchers validate the specificity of R4 antibodies in their experimental systems?

Validating R4 antibody specificity requires multiple complementary approaches:

• Cross-reactivity testing: Test antibodies against related antigens to ensure they recognize only the intended target. For R4 protein of Streptococcus agalactiae, this involves testing against other GBS proteins like Cα, Cβ, and R3 .

• Competition ELISA: This technique assesses whether different antibodies target the same binding site. For example, to determine if monoclonal and polyclonal R4 antibodies recognize the same epitope, researchers can perform a competition assay where one antibody is used to block the binding of another:

  • Coat microtiter plates with R4 protein

  • Add first antibody (e.g., rabbit antiserum) at a dilution corresponding to ELISA titer divided by 10

  • Incubate at 20°C for 60 min

  • Wash plates

  • Add second antibody (e.g., monoclonal antibody) in various dilutions

  • Proceed with standard ELISA detection using appropriate conjugates

• Fluorescent-antibody test (FAT): A whole-cell-based indirect immunofluorescence assay can validate antibody specificity in intact bacterial systems. Fluorescence is graded from 0 to 3+, with scores of 2+ and 3+ indicating positive results .

• PCR validation: Confirm antibody target expression by PCR. For instance, PCR for genes encoding target proteins (e.g., alp2, alp3, and rib encoding Alp2, Alp3, and R4 respectively) can verify the presence of the genes corresponding to the proteins recognized by the antibodies .

What considerations are important when designing experiments with cell-internalizing R4 antibodies?

When designing experiments with cell-internalizing R4 antibodies such as anti-Robo4:

• Selection of appropriate antibody format: Consider whether scFv, dscFv, IgG, or modified formats like scFv-PSIF are most appropriate for your experimental needs. Each format demonstrates different binding kinetics and internalization properties .

• Controls for internalization: Include low-internalizing antibody controls (e.g., R4-16 for Robo4) that have similar affinity but different internalization properties to properly assess the contribution of internalization to experimental outcomes .

• Consideration of conjugation effects: If developing antibody-drug conjugates (ADCs), assess how conjugation affects binding kinetics. For example, IgG-NCS conjugates should maintain similar binding properties to unconjugated IgG .

• Scale-down models: When developing processes for antibody-drug conjugates, select appropriate scale-down models to avoid introducing undesired variability during execution, which would negatively impact the ability to model the true process effects .

• Biodistribution studies: For therapeutic applications, compare tumor accumulation between high-internalizing and low-internalizing antibodies with similar binding affinities to assess the contribution of internalization to therapeutic efficacy .

How are R4 antibodies being utilized in cutting-edge cancer research?

R4 antibodies are at the forefront of next-generation cancer therapeutics, particularly in the development of antibody-drug conjugates (ADCs) targeting tumor vasculature:

• Tumor vascular targeting: Anti-Robo4 antibodies with high cell-internalizing activity have demonstrated significant efficacy in targeting tumor blood vessels. Research has shown that Robo4 can be an effective marker for tumor vascular targeting with an improved safety profile compared to other targets like VEGFR2 .

• Enhanced tumor accumulation: Cell-internalizing anti-Robo4 antibodies demonstrate significantly higher tumor accumulation than antibodies with low cell-internalizing activity, even when binding affinities are similar. This enhanced accumulation translates directly to improved therapeutic outcomes .

• Reduced side effects: Comparative studies between anti-Robo4 and anti-VEGFR2 therapies have revealed that anti-Robo4 treatment causes fewer side effects. While anti-VEGFR2 therapy resulted in significant body weight loss in experimental models, anti-Robo4 therapy did not produce this adverse effect, suggesting a superior therapeutic window .

• Residualizing radiolabels: Advanced radioimmunotherapy using R4-related technology involves residualizing iodine radiolabels. The IMP-R4 adduct (consisting of a nonmetabolizable peptide attached to diethylenetriaminepentaacetic acid) causes radioiodine to become trapped in lysosomes following antibody catabolism, significantly improving retention time within target cells and enhancing therapeutic efficacy .

What role do R4 antibodies play in immunological marker research for infectious diseases?

R4 antibodies are crucial tools in characterizing immune responses to bacterial pathogens, particularly Streptococcus agalactiae (Group B Streptococcus or GBS):

• Serotyping and strain differentiation: R4 antibodies enable precise serotyping of GBS strains, which is essential for epidemiological studies and vaccine development. Research has demonstrated that of 60 clinical serotype III GBS strains, 56 (93%) isolates possessed the rib gene encoding R4 protein, and 50 (89%) of the rib-positive isolates expressed detectable levels of R4 .

• Antigenic determinant characterization: Studies using R4 antibodies have revealed that the R4 protein possesses two distinct antigenic determinants: one shared with Alp3 protein (R4/Alp3 common) and another unique to R4 (R4 specific). This discovery has significant implications for understanding cross-reactivity between bacterial strains and developing specific diagnostic tests .

• Correlation between gene possession and expression: R4 antibody-based tests combined with PCR analysis have revealed that approximately 10% of rib-positive GBS strains fail to express R4 protein or express it at levels too low for antibody detection. This finding has important implications for diagnostic test development and understanding bacterial virulence mechanisms .

• Vaccine component evaluation: R4 and related proteins are being evaluated as potential GBS vaccine components, with R4 antibodies playing a crucial role in assessing the immunobiological function of each distinct antigenic determinant .

How can researchers utilize R4 antibodies in neurodegenerative disease studies?

R4 domain-targeting antibodies are emerging as promising tools in neurodegenerative disease research, particularly for tauopathies like Alzheimer's disease:

• Mid-domain targeting strategy: While antibodies targeting the N-terminal or C-terminal regions of tau protein have shown limited efficacy in clinical trials, research has indicated that antibodies targeting tau's microtubule-binding region (MTBR), which contains the R1-R4 repeat domains, may be more effective at preventing pathological tau aggregation and spreading .

• Prevention of aggregate seeding: R4 domain-targeting antibodies have demonstrated superior ability to prevent uptake of tau aggregates in cell culture models. For example, bepranemab, which recognizes residues 235–250 in the MTBR (overlapping with R1), prevented tau aggregate uptake at concentrations as low as 0.3 nM, while N-terminal antibodies required more than 10 times that concentration to achieve similar effects .

• Clinical trial design considerations: Based on preclinical success with R4 domain-targeting antibodies, researchers are designing trials with longer observation periods to capture meaningful clinical outcomes. Expert consensus suggests that one-year trials may be too short to detect the effects of these antibodies, and extended trials focusing on survival or other long-term outcomes would better serve the field .

• Biomarker correlation: Advanced research using R4 domain-targeting antibodies has been informed by cerebrospinal fluid (CSF) biomarker studies demonstrating that MTBR tau fragments in CSF correlate with tangle pathology, providing a potential pharmacodynamic marker for these therapeutic antibodies .

What are common challenges in R4 antibody research and how can they be addressed?

Researchers working with R4 antibodies face several technical challenges:

• Epitope misidentification: As demonstrated with the R4 monoclonal antibody F39, antibodies previously considered R4-specific may actually target shared epitopes (like the R4/Alp3 common determinant). This can lead to false identification of related proteins. Solution: Perform thorough cross-absorption studies with related antigens and validate specificity using multiple complementary techniques including competition ELISA and PCR verification of target genes .

• Variability in protein expression: Approximately 10% of bacteria possessing the gene encoding R4 (rib) fail to express detectable levels of the protein. Solution: Use both antibody-based detection methods and molecular techniques like PCR to verify both the presence of the gene and its expression .

• Conjugate compatibility in vaccines: When using R4 antibodies to study vaccine responses, interactions between vaccine components containing similar conjugates can affect immunogenicity. For example, MenACWY-D (Menactra) demonstrates reduced immunogenicity when administered simultaneously with PCV13. Solution: Space administration of vaccines containing similar conjugates by 28 days, particularly in persons with anatomic asplenia .

• Internalization efficiency variation: Cell-internalizing antibodies like anti-Robo4 can show variable internalization efficiency despite similar binding affinities. Solution: Implement high-throughput screening systems to isolate antibodies with optimal internalization properties and include proper low-internalizing controls in experiments .

How can researchers optimize detection methods when working with R4 antibodies?

Optimization strategies for R4 antibody-based detection include:

• Indirect ELISA optimization:

  • Determine optimal coating concentration through checkerboard titration (1:10 dilution has been shown optimal for GBS R4 protein)

  • Use appropriate blocking agents to minimize background

  • Select optimal antibody dilutions (1:500 for PAbs and MAbs, 1:2,000 for gamma globulin preparations)

  • Incubate with alkaline phosphatase-conjugated secondary antibodies at 1:1,000 dilution

  • Perform incubations at optimal temperature (20°C for 1 hour has been effective)

• Fluorescent-antibody test enhancement:

  • Use antibody dilution of 1:40 to generate strong positive reactions (3+) with positive-control isolates

  • Ensure negative test results with negative-control strains

  • Follow manufacturer recommendations for fluorescent anti-IgG conjugates

  • Grade fluorescence from 0 to 3+, with scores of 2+ and 3+ considered positive

• Balancing sensitivity and specificity:

  • For R4 detection in Streptococcus agalactiae, using antibodies targeting only the R4-specific determinant ensures detection of only R4, while antibodies targeting the R4/Alp3 common determinant will detect both R4 and Alp3

  • Choose antibodies based on whether discrimination between closely related proteins is required

• Simultaneous use of multiple detection methods:

  • Combine antibody-based detection with PCR verification of target genes

  • Use competition ELISA to verify epitope specificity

  • Incorporate positive and negative controls to ensure assay functionality

What are the latest developments in R4 antibody technology for improved therapeutic outcomes?

Recent advances in R4 antibody technology have focused on enhancing therapeutic efficacy:

• Residualizing radiolabels: The development of IMP-R4, a radiolabeling technique where radioiodine is introduced onto antibodies using an adduct consisting of a nonmetabolizable peptide attached to diethylenetriaminepentaacetic acid, has significantly improved radioiodine retention within target cells. This advancement has led to increased radioiodine accretion in human tumor xenografts and marked improvement in therapeutic efficacy .

• Cell-internalizing antibody screening: High-throughput screening systems combining phage display with PSIF-based detection have revolutionized the isolation of cell-internalizing antibodies. This approach allows simultaneous examination of cell-internalizing activities of hundreds of monoclonal candidates in a single step, dramatically accelerating the development of effective antibody-drug conjugates .

• Domain-specific targeting: For neurodegenerative diseases, research has shifted from N-terminal tau antibodies to those targeting the microtubule-binding region (MTBR) containing R1-R4 domains. This shift is based on evidence that mid-domain antibodies better prevent pathological tau spreading, with several such antibodies now advancing in clinical trials .

• Design of experiments (DOE) for process development: Advanced statistical approaches are being applied to optimize antibody-drug conjugate development. Full factorial design experiments with corner points and center-points are being used to ensure consistent Drug Antibody Ratio (DAR) within target ranges (e.g., 3.4-4.4 with an ideal target of 3.9) .

How are R4 antibodies contributing to our understanding of disease mechanisms?

R4 antibodies are providing critical insights into fundamental disease processes:

• Tumor vasculature targeting: Research with cell-internalizing anti-Robo4 antibodies has revealed that internalization activity plays a crucial role in the biodistribution and therapeutic effects of antibody-drug conjugates. These findings have important implications for understanding tumor vascular biology and developing targeted cancer therapies .

• Differential effects of vascular targeting: Comparative studies between anti-Robo4 and anti-VEGFR2 therapies have shown that while both can effectively target tumor vasculature, anti-Robo4 therapy produces fewer side effects. This suggests different biological roles for these receptors in normal versus tumor vasculature, opening new avenues for selective therapeutic targeting .

• Tau pathology propagation: Studies with R4 domain-targeting antibodies have provided evidence that the microtubule-binding region of tau, particularly the R1-R4 repeat domains, is critical for pathological tau spreading in neurodegenerative diseases. This has shifted the understanding of tau pathology from a static to a propagating model of disease progression .

• Antigen-presenting cell function during infection: R4 antibodies have been used to investigate how antigen-presenting cell function is altered during infections like Plasmodium yoelii. Research has shown that T-cell proliferative responses are inhibited during infection, with naive T cells exhibiting diminished IL-2 production in the presence of antigen-presenting cells from infected mice .

What novel combinations of R4 antibodies with other technologies are showing promise?

Innovative combinations of R4 antibodies with other technologies are creating powerful new research and therapeutic tools:

• Antibody-drug conjugates with residualizing labels: The combination of cell-internalizing antibodies like anti-Robo4 with residualizing labels such as IMP-R4 is showing enhanced therapeutic potential. This approach improves both targeting specificity and intracellular retention of therapeutic payloads .

• Integration with cerebrospinal fluid biomarkers: The development of R4 domain-targeting antibodies for neurodegenerative diseases is being guided by advances in CSF biomarker research. For example, the correlation between CSF MTBR tau fragments and tangle pathology is informing the design and evaluation of therapeutic antibodies targeting this region .

• High-throughput screening with phage display: The combination of phage antibody libraries with high-throughput cell internalization assays has revolutionized the discovery of therapeutic antibodies. This approach allows for rapid identification of antibodies with optimal properties for specific applications, such as tumor vascular targeting .

• Design of experiments (DOE) for process development: The application of statistical DOE approaches to antibody-drug conjugate development enables more efficient optimization of process parameters. For example, full factorial design with 16 experiments in corners and three center-points has been used to optimize Drug Antibody Ratio while minimizing the number of experiments required .

What are the typical binding kinetics for effective R4 antibodies?

Table 1: Binding Kinetics of Anti-Robo4 and Anti-VEGFR2 Antibodies in Various Formats

This table provides reference values for binding kinetics of effective R4 antibodies in different formats, showing association rates (ka), dissociation rates (kd), and equilibrium dissociation constants (KD). Note that high-affinity antibodies typically demonstrate ka values in the range of 10^6 M^-1s^-1 and kd values in the range of 10^-4 s^-1, resulting in KD values in the picomolar range .

What are the critical expression patterns of R4 targets in different tissues?

For R4 antigen (CD1A gene product):

• Primarily localized in the cell membrane

• Notably expressed in tonsil, thymus, and skin

• Canonical protein length: 327 amino acid residues

• Protein mass: 37.1 kilodaltons

For Robo4:

• Predominantly expressed in tumor endothelial cells

• Low expression in normal vasculature

• Serves as an effective marker for tumor vascular targeting

• Targeting Robo4 produces fewer side effects than targeting VEGFR2, suggesting limited expression in essential normal tissues

For R4 protein of Streptococcus agalactiae:

• Expressed in approximately 89% of strains possessing the rib gene

• Expression detected by antibody-based tests in 50 out of 56 rib-positive isolates

• Not detected in strains expressing only Cα, Cβ, Alp2, or R3 proteins

What experimental parameters are critical for successful R4 antibody applications?

Critical Parameters for Effective R4 Antibody Use:

• Optimal antibody concentrations for detection methods:

  • For ELISA: PAbs and MAbs at 1:500 dilution

  • For gamma globulin preparations: 1:2,000 dilution

  • For fluorescent-antibody test: 1:40 dilution

• Incubation conditions:

  • Temperature: 20°C is optimal for most applications

  • Duration: 60 minutes for primary and secondary antibody incubations

• Design space for antibody-drug conjugate development:

  • Drug Antibody Ratio (DAR): Target range 3.4-4.4

  • Optimal set-point: 3.9

  • Experimental design: Full factorial design with 16 experiments in corners and three center-points

• Vaccine administration timing when using antibodies to assess response:

  • For vaccines containing similar conjugates (e.g., MenACWY-D and PCV13): Space by 28 days in persons with anatomic asplenia

  • For MCV4-CRM (Menveo), PCV13, and Tdap: Can be administered simultaneously or sequentially without reduced immunogenicity

• Residualizing radiolabel parameters:

  • IMP-R4 peptide conjugation to reduced mAb

  • Direct radioiodination by chloramine-T method

  • Assessment of immunoreactivity by size exclusion high-performance liquid chromatography following incubation with antigen